Keywords: AstraZeneca, Crestor, Pfizer, Lipitor, SATURN trial

AstraZeneca’s Crestor fails to show significant improvement over Lipitor

Article | 05 September 2011

Print This

There was a big disappointment for Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Friday, when it revealed results of a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in